Arthritis Foundation announces top 10 arthritis advances in 2005
Posted on Sunday, February 5, 2006
The recent approval of a first-in-class biologic drug for rheumatoid arthritis, the proven safety of oral contraceptives in women with lupus, and development of the first new drug for gout in 40 years are among the 10 most significant arthritis advances of 2005, according to the Arthritis Foundation.
Other big news in the past year— the withdrawal of two popular arthritis pain medications and more stringent warnings on nonsteroidal anti-inflammatory drugs — may have confused the public and shaken its confidence in arthritis therapies. However, new understanding of the importance of personal lifestyle choices in relieving pain and novel treatments in the pipeline provide more hope than ever in the year ahead for people of all ages suffering from the most serious and debilitating forms of arthritis and related diseases. "Advances made in 2005 promise a better quality of life for patients with arthritis and related diseases in the year ahead and hint at breakthroughs that are possible in the future," said Tracey Meyer Chesser, of the Arthritis Foundation. "As the nation ages and the number of people with arthritis increases, advances in research, public health and public policy will contribute to the prevention, control and cure of arthritis – the nation’s number one cause of disability."
Abatacept, the first biologic in a class of co-stimulation modulators for RA, was approved by the U.S. Food and Drug Administration on December 23, 2005, making another treatment option available for patients in the year ahead. With an early 2006 decision expected on another biologic, rituximab, arthritis patients have more treatment options on the horizon than ever before and more hope for therapeutic approaches that target the basic causes of their disease, which reduce both disease symptoms and the risk of disability.
The top 10 advances:
• New biologic drugs for rheumatoid arthritis
• First new drug for gout in 40 years
• Historic Medicare program expansion
• Lifestyle choices reduce pain and improve function
• Improvements in osteoporosis patient compliance and quality of life
• First new lupus drug in nearly 40 years; safety of oral contraceptives in lupus
• Evidence-based treatment recommendations for juvenile arthritis
• Greater understanding of arthritis drug risks
• Osteoporosis drug delays osteoarthritis joint destruction
• Discovery of key regulator of autoimmunity
Summaries of each of the top arthritis advances, as well as what they mean for arthritis patients in the year ahead, are available at www. arthritis. org. To develop its third annual list of the Top 10 arthritis advances, the Arthritis Foundation sought input from clinicians with expertise in various forms of arthritis, scientists from a wide variety of research disciplines, and organizations with an interest in arthritis and related diseases.
FEEDBACK:
Something to say about this topic? Submit a Letter to the Editor online
